Valsartan is one of the world’s most widely prescribed medications for the treatment of high blood pressure. It is effective for treating high blood pressure and heart failure, and for reducing the chance of cardiovascular mortality following a myocardial infarction. Unfortunately, a recent nationwide recall revealed that many batches of the drug already distributed and given to patients contained cancer-causing substances that put the lives of hundreds of thousands of people at risk.
In July 2018, the U.S. Food and Drug Administration (FDA), along with several health and safety agencies in other countries, issued recalls for numerous medications containing Valsartan after discovering the presence of N-nitrosodimethylamine (NDMA), a known carcinogen. Thereafter, in September 2018, the FDA learned that three batches of Valsartan manufactured by Torrent Pharmaceuticals also contained traces of another carcinogenic impurity, N-nitrosodiethylamine (NDEA).
Berman & Simmons is pursuing Valsartan and Losartan-related claims
As of March 2019, the FDA’s list of recalled products contains dozens of variations of Valsartan-containing medications from multiple manufacturers. If you took Valsartan or Losartan and were subsequently diagnosed with cancer of the digestive track such as colorectal, stomach, liver, bladder, and pancreatic cancer, you may deserve compensation for your illness and losses.
Berman & Simmons is pursuing compensation for the damages suffered by individuals in Maine and throughout New England who may have claims against Valsartan and Losartan manufacturers for the cancer they developed after taking the drug. We have the experience, legal skill, and medical resources to get you full compensation and to hold pharmaceutical companies accountable for the harm they inflict when they put their profits ahead of the safety of those who use their products.
